insights_auto
Outlook: 77.5% bullish·0.0% bearish
Go to analysischevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
753,12 $
arrow_downward
-1,27%(-9,69) 1D
753,12 $
0,00% (0,00)
bedtimeAfter hours
Closed: 13 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
762,48 $
High
765,60 $
Low
743,57 $
Mkt. cap
77,54 млрд
Avg. vol.
714,98 м.
Volume
629,56 м.
Dividend
0,50%
Quarterly dividend
0,94 $
Ex-dividend date
2026 ж. 18 там.
P/E ratio
18,62
52-wk high
859,34 $
52-wk low
553,86 $
EPS
40,45 $
Beta
0,16
Shares outstanding
101,14 млн
No. of employees
15 мың
Open
762,48 $
High
765,60 $
Low
743,57 $
Mkt. cap
77,54 млрд
Avg. vol.
714,98 м.
Volume
629,56 м.
Dividend
0,50%
Quarterly dividend
0,94 $
Ex-dividend date
2026 ж. 18 там.
P/E ratio
18,62
52-wk high
859,34 $
52-wk low
553,86 $
EPS
40,45 $
Beta
0,16
Shares outstanding
101,14 млн
No. of employees
15 мың
News stories
From web sources and news partners
News Corp
·
5 сағат бұрын
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
ad-hoc-news.de
·
11 сағат бұрын
RBC raises target for Regeneron stock to USD 810.00
Zacks
·
12 сағат бұрын
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Globe and Mail
·
15 сағат бұрын
Citi Keeps Their Hold Rating on Regeneron (REGN)
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15,3 мың
Founded1988
HeadquartersTarrytown, Нью-Йорк, Америка Құрама Штаттары
Sector-
Websiteregeneron.com